Safety and Tolerability of Adalimumab Treatment. Adverse Events: Medical Occurrence in a Patient or Clinical Investigation Subject Administered a Pharmaceutical Product and Which Does Not Necessarily Have a Causal Relationship With the Treatment Baseline, 1, 4, 6, and 12 months [clinicaltrials_resource:72cd303abbfb1e5b65d2a54222be1645]
The safety and tolerability of adalimumab was assessed at each study visit. The overall number of participants experiencing serious adverse events (SAEs), non-serious adverse events (AEs) and AEs that led to discontinuation are presented. The number of participants presenting with any serious or non-serious event at each particular study visit is also reported. Note that for the incidence data participants were counted multiple times if they experienced an adverse event at more than 1 visit. For additional information see Reported Adverse Events.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Safety and Tolerability of Adalimumab Treatment. Adverse Events: Medical Occurrence in a Patient or Clinical Investigation Subject Administered a Pharmaceutical Product and Which Does Not Necessarily Have a Causal Relationship With the Treatment Baseline, 1, 4, 6, and 12 months [clinicaltrials_resource:72cd303abbfb1e5b65d2a54222be1645]
The safety and tolerability of adalimumab was assessed at each study visit. The overall number of participants experiencing serious adverse events (SAEs), non-serious adverse events (AEs) and AEs that led to discontinuation are presented. The number of participants presenting with any serious or non-serious event at each particular study visit is also reported. Note that for the incidence data participants were counted multiple times if they experienced an adverse event at more than 1 visit. For additional information see Reported Adverse Events.
Bio2RDF identifier
72cd303abbfb1e5b65d2a54222be1645
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:72cd303abbfb1e5b65d2a54222be1645
measure [clinicaltrials_vocabulary:measure]
Safety and Tolerability of Ada ...... elationship With the Treatment
time frame [clinicaltrials_vocabulary:time-frame]
Baseline, 1, 4, 6, and 12 months
description
The safety and tolerability of ...... n see Reported Adverse Events.
identifier
clinicaltrials_resource:72cd303abbfb1e5b65d2a54222be1645
title
Safety and Tolerability of Ada ...... seline, 1, 4, 6, and 12 months
@en
type
label
Safety and Tolerability of Ada ...... d303abbfb1e5b65d2a54222be1645]
@en